Sage Journals: Discover world-class research

Retricted access

Review article

First published 2022-1

A contemporary review of rearranged during transfection-selective inhibitors

Angel W Liu, Connie Liang, Chung-Shien Lee

Journal of Oncology Pharmacy Practice

Open access

Research article

First published 2024-01

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Vivek Subbiah, Mimi I. Hu, Aaron S. Mansfield [...]

Thyroid®

Retricted access

Research article

First published 2021-02

Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy

Justine Y. Bruce, Keith C. Bible, Ashish V. Chintakuntlawar

Thyroid®

Retricted access

Correction

First published 2025-07

Correction to : Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study’’ by Subbiah et al. Thyroid 2024;34(1):26–40;doi: 10.1089/thy.2023.0363

Thyroid®

Open access

Review article

First published 2023

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China

Tao Li, Wen-Yu Yang, Ting-Ting Liu [...]

Technology in Cancer Research & Treatment

Open access

Review article

First published 2020

Current management of RET rearranged non-small cell lung cancer

Thomas E Stinchcombe

Therapeutic Advances in Medical Oncology

Open access

Case report

First published 2022-6

Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report

Xiangming Cao, Xiongwei Liu, Simin Wang [...]

Journal of International Medical Research

Open access

Review article

First published 2012

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer

Nils Degrauwe, Julie Ann Sosa, Sanziana Roman [...]

Clinical Medicine Insights: Oncology

Open access

Case report

First published 2026

Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report

Shiwei Chen, He Wang, Qi Shen [...]

Therapeutic Advances in Endocrinology and Metabolism

Open access

Review article

First published 2023

Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers

Mohamed A. Gouda, Vivek Subbiah

Therapeutic Advances in Medical Oncology

Search results